Cargando…

Mechanism of diabetic neuropathy: Where are we now and where to go?

Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagihashi, Soroku, Mizukami, Hiroki, Sugimoto, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008011/
https://www.ncbi.nlm.nih.gov/pubmed/24843457
http://dx.doi.org/10.1111/j.2040-1124.2010.00070.x
_version_ 1782314386809946112
author Yagihashi, Soroku
Mizukami, Hiroki
Sugimoto, Kazuhiro
author_facet Yagihashi, Soroku
Mizukami, Hiroki
Sugimoto, Kazuhiro
author_sort Yagihashi, Soroku
collection PubMed
description Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines, activation of protein kinase C and exaggerated oxidative stress, as well as other confounding factors. Although these metabolic aberrations are deemed as the main stream for the pathogenesis of diabetic microvascular complications, organ‐specific histological and biochemical characteristics constitute distinct mechanistic processes of neuropathy different from retinopathy or nephropathy. Extremely long axons originating in the small neuronal body are vulnerable on the most distal side as a result of malnutritional axonal support or environmental insults. Sparse vascular supply with impaired autoregulation is likely to cause hypoxic damage in the nerve. Such dual influences exerted by long‐term hyperglycemia are critical for peripheral nerve damage, resulting in distal‐predominant nerve fiber degeneration. More recently, cellular factors derived from the bone marrow also appear to have a strong impact on the development of peripheral nerve pathology. As evident from such complicated processes, inhibition of single metabolic factors might not be sufficient for the treatment of neuropathy, but a combination of several inhibitors might be a promising approach to overcome this serious disorder. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00070.x, 2010)
format Online
Article
Text
id pubmed-4008011
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-40080112014-05-19 Mechanism of diabetic neuropathy: Where are we now and where to go? Yagihashi, Soroku Mizukami, Hiroki Sugimoto, Kazuhiro J Diabetes Investig Review Articles Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines, activation of protein kinase C and exaggerated oxidative stress, as well as other confounding factors. Although these metabolic aberrations are deemed as the main stream for the pathogenesis of diabetic microvascular complications, organ‐specific histological and biochemical characteristics constitute distinct mechanistic processes of neuropathy different from retinopathy or nephropathy. Extremely long axons originating in the small neuronal body are vulnerable on the most distal side as a result of malnutritional axonal support or environmental insults. Sparse vascular supply with impaired autoregulation is likely to cause hypoxic damage in the nerve. Such dual influences exerted by long‐term hyperglycemia are critical for peripheral nerve damage, resulting in distal‐predominant nerve fiber degeneration. More recently, cellular factors derived from the bone marrow also appear to have a strong impact on the development of peripheral nerve pathology. As evident from such complicated processes, inhibition of single metabolic factors might not be sufficient for the treatment of neuropathy, but a combination of several inhibitors might be a promising approach to overcome this serious disorder. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00070.x, 2010) Blackwell Publishing Ltd 2011-01-24 2010-10-06 /pmc/articles/PMC4008011/ /pubmed/24843457 http://dx.doi.org/10.1111/j.2040-1124.2010.00070.x Text en © 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd
spellingShingle Review Articles
Yagihashi, Soroku
Mizukami, Hiroki
Sugimoto, Kazuhiro
Mechanism of diabetic neuropathy: Where are we now and where to go?
title Mechanism of diabetic neuropathy: Where are we now and where to go?
title_full Mechanism of diabetic neuropathy: Where are we now and where to go?
title_fullStr Mechanism of diabetic neuropathy: Where are we now and where to go?
title_full_unstemmed Mechanism of diabetic neuropathy: Where are we now and where to go?
title_short Mechanism of diabetic neuropathy: Where are we now and where to go?
title_sort mechanism of diabetic neuropathy: where are we now and where to go?
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008011/
https://www.ncbi.nlm.nih.gov/pubmed/24843457
http://dx.doi.org/10.1111/j.2040-1124.2010.00070.x
work_keys_str_mv AT yagihashisoroku mechanismofdiabeticneuropathywherearewenowandwheretogo
AT mizukamihiroki mechanismofdiabeticneuropathywherearewenowandwheretogo
AT sugimotokazuhiro mechanismofdiabeticneuropathywherearewenowandwheretogo